Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien

Fri Aug 1, 2014 9:20am EDT

* Reuters is not responsible for the content in this press release.

Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 1, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.

Mylan, Inc. Research Reports
On July 23, 2014, Mylan, Inc. (Mylan) announced that it has won motion for temporary restraining order from the U.S. District Court, blocking Apotex Inc. and Apotex Corporation from selling a generic version of GlaxoSmithKline's Paxil® CR. The development came almost a week after the District Court prohibited GlaxoSmithKline (GSK) from supplying Paroxetine CR to Apotex, which marketed the product as an authorized generic. In its latest ruling, the Court has also ordered Apotex to immediately recall all product from its direct customers that was shipped since the injunction was entered against GSK on July 16, 2014. According to Mylan, it has an exclusive license to an Orange Book patent pertaining to Paxil CR which expires in July 2016, with pediatric exclusivity extending until January 19, 2017. Mylan also believes that it is the only company to have successfully developed an FDA-approved generic version of this product. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Aug-01-2014/MYL/report.pdf

Biogen Idec Inc. Research Reports
On July 23, 2014, Biogen Idec Inc. (Biogen) announced its Q2 2014 financial results. Helped by the increased adoption of its TECFIDERA® in the U.S. and new markets worldwide, the Company's Q2 2014 adjusted diluted EPS jumped 51.7% YoY to $3.49. Biogen's Q2 2014 earnings surpassed Wall Street expectations, sending the stock up by as much as 13.15% on the day of announcement. On average, analysts polled by Reuters had expected the Company to report adjusted diluted EPS of $2.83. Investors also cheered the Company's revised full-year 2014 outlook. Biogen now expects adjusted diluted EPS to be between $12.90 and $13.10. Biogen's revenues during the quarter also jumped 40.5% YoY to $2.4 billion, which is about $250 million above market expectations, according to Reuters. TECFIDERA revenues were $700 million, consisting of $585 million in U.S. sales and $115 million in sales outside the U.S. The full research reports on Biogen are available to download free of charge at:

http://www.analystsreview.com/Aug-01-2014/BIIB/report.pdf

Medtronic, Inc. Research Reports
On July 28, 2014, Medtronic, Inc. (Medtronic) announced that it has completed the acquisition of Texas-based Visualase, Inc. (Visualase) in an all-cash transaction of up to $105 million. Medtronic, which already held an ownership stake in Visualase prior to completion of the acquisition, will make an upfront payment of $70 million plus additional payments of up to $35 million which are contingent upon achievement of specific milestones. Following the acquisition, Medtronic will add Visualase's FDA-approved MRI-guided laser and image guided system to its portfolio of therapies for treating neurological conditions within its Surgical Technologies business. The transaction is expected to boost the Company's neurosurgical solutions portfolio, which includes intra-operative imaging, surgical navigation, powered instruments and cerebrospinal fluid (CSF) management. The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Aug-01-2014/MDT/report.pdf

UnitedHealth Group Inc. Research Reports
On July 29, 2014, UnitedHealth Group Inc. (UnitedHealth) announced that its subsidiary UnitedHealthcare has entered into a new, three-year agreement with Tenet Healthcare Corporation (Tenet) to provide consumers an uninterrupted access to quality care at Tenet's hospitals in their local communities. According to the Company, the agreement provides UnitedHealthcare's Commercial and Medicare Advantage members with in-network access to Tenet's 79 hospitals, 193 outpatient centers and more than 1,800 employed physicians throughout the country, effective from August 1, 2014. Commenting on the development, UnitedHealthcare Networks' President Dan Rosenthal said, "We are pleased to renew this national contract with Tenet which gives our members access to providers focused on driving care improvements and offers competitive reimbursement rates, a portion of which, importantly, rewards Tenet for achieving certain quality measures." The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Aug-01-2014/UNH/report.pdf

Covidien plc Research Reports
On July 25, 2014, Covidien plc (Covidien) announced its Q3 FY 2014 financial results (period ended June 27, 2014). The Company's net sales during the quarter grew 4.3% YoY to $2.7 billion. Covidien, which is into an agreement to be acquired by Medtronic, said its net income during the quarter declined to $306 million, or $0.67 per diluted share, from $400 million, or $0.84 per diluted share, in Q3 FY 2013. The adjusted diluted income from continuing operations was up by 14.3% YoY at $1.04 per share, beating the average forecast of $1.00 in a Reuters' poll of analysts. In June 2014, Medtronic had agreed to acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Aug-01-2014/COV/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com

SOURCE Analysts Review

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.